XTRA:GXILife Sciences
A Look at Gerresheimer (XTRA:GXI) Valuation After FDA Approval of New On-Body Drug Delivery Device
Gerresheimer (XTRA:GXI) shares drew renewed attention after news that the US FDA approved the Lasix ONYU combination product, which features the company’s proprietary on-body drug delivery device. This regulatory win could prove commercially meaningful with 2025 launches approaching.
See our latest analysis for Gerresheimer.
Despite the lift from FDA approval of its new drug delivery device, Gerresheimer's share price has continued to face heavy pressure, with a 30-day share price return of...